Loading...

Safe Orthopaedics

ENXTPA:SAFOR
Snowflake Description

Slightly overvalued with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SAFOR
ENXTPA
€6M
Market Cap
  1. Home
  2. FR
  3. Healthcare
Company description

Safe Orthopaedics, SA, a medical technology company, provides a range of sterile implants and associated single-use surgical instruments for use in spinal surgery in France. The last earnings update was 205 days ago. More info.


Add to Portfolio Compare Print
  • Safe Orthopaedics has significant price volatility in the past 3 months.
SAFOR Share Price and Events
7 Day Returns
1.7%
ENXTPA:SAFOR
-5.2%
FR Medical Equipment
1.3%
FR Market
1 Year Returns
-70.3%
ENXTPA:SAFOR
1.5%
FR Medical Equipment
3.6%
FR Market
SAFOR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Safe Orthopaedics (SAFOR) 1.7% -0.6% -5.8% -70.3% -92.3% -
FR Medical Equipment -5.2% -0.4% 14% 1.5% 39.4% 59.8%
FR Market 1.3% 3.8% 14.3% 3.6% 28.9% 33.6%
1 Year Return vs Industry and Market
  • SAFOR underperformed the Medical Equipment industry which returned 1.5% over the past year.
  • SAFOR underperformed the Market in France which returned 3.6% over the past year.
Price Volatility
SAFOR
Industry
5yr Volatility vs Market
Related Companies

SAFOR Value

 Is Safe Orthopaedics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Safe Orthopaedics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Safe Orthopaedics.

ENXTPA:SAFOR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.3%
Perpetual Growth Rate 10-Year FR Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTPA:SAFOR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year FR Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.7%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.928 (1 + (1- 33%) (80.32%))
1.286
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.29
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (1.286 * 6.65%)
9.29%

Discounted Cash Flow Calculation for ENXTPA:SAFOR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Safe Orthopaedics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTPA:SAFOR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 9.29%)
2019 -6.15 Analyst x2 -5.63
2020 -4.80 Analyst x2 -4.02
2021 -3.20 Analyst x1 -2.45
2022 -0.10 Analyst x1 -0.07
2023 1.30 Analyst x1 0.83
2024 2.13 Est @ 64.01% 1.25
2025 3.09 Est @ 45.02% 1.66
2026 4.07 Est @ 31.74% 2.00
2027 4.99 Est @ 22.44% 2.24
2028 5.78 Est @ 15.93% 2.38
Present value of next 10 years cash flows €-1.80
ENXTPA:SAFOR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €5.78 × (1 + 0.73%) ÷ (9.29% – 0.73%)
€68.08
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €68.08 ÷ (1 + 9.29%)10
€28.01
ENXTPA:SAFOR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €-1.80 + €28.01
€26.21
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €26.21 / 41.20
€0.64
ENXTPA:SAFOR Discount to Share Price
Calculation Result
Value per share (EUR) From above. €0.64
Current discount Discount to share price of €0.15
= -1 x (€0.15 - €0.64) / €0.64
75.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Safe Orthopaedics is available for.
Intrinsic value
>50%
Share price is €0.154 vs Future cash flow value of €0.63619
Current Discount Checks
For Safe Orthopaedics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Safe Orthopaedics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Safe Orthopaedics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Safe Orthopaedics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Safe Orthopaedics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:SAFOR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.25
ENXTPA:SAFOR Share Price ** ENXTPA (2019-04-18) in EUR €0.15
Europe Medical Equipment Industry PE Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 30.1x
France Market PE Ratio Median Figure of 418 Publicly-Listed Companies 16.34x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Safe Orthopaedics.

ENXTPA:SAFOR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:SAFOR Share Price ÷ EPS (both in EUR)

= 0.15 ÷ -0.25

-0.61x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Safe Orthopaedics is loss making, we can't compare its value to the Europe Medical Equipment industry average.
  • Safe Orthopaedics is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does Safe Orthopaedics's expected growth come at a high price?
Raw Data
ENXTPA:SAFOR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.61x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Europe Medical Equipment Industry PEG Ratio Median Figure of 39 Publicly-Listed Medical Equipment Companies 2.28x
France Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Safe Orthopaedics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Safe Orthopaedics's assets?
Raw Data
ENXTPA:SAFOR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €-0.08
ENXTPA:SAFOR Share Price * ENXTPA (2019-04-18) in EUR €0.15
France Medical Equipment Industry PB Ratio Median Figure of 25 Publicly-Listed Medical Equipment Companies 2.12x
France Market PB Ratio Median Figure of 619 Publicly-Listed Companies 1.49x
ENXTPA:SAFOR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:SAFOR Share Price ÷ Book Value per Share (both in EUR)

= 0.15 ÷ -0.08

-1.96x

* Primary Listing of Safe Orthopaedics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Safe Orthopaedics has negative assets, we can't compare the value of its assets to the FR Medical Equipment industry average.
X
Value checks
We assess Safe Orthopaedics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Safe Orthopaedics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SAFOR Future Performance

 How is Safe Orthopaedics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
33%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Safe Orthopaedics expected to grow at an attractive rate?
  • Unable to compare Safe Orthopaedics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Safe Orthopaedics's earnings growth to the France market average as no estimate data is available.
  • Safe Orthopaedics's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:SAFOR Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:SAFOR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 33%
France Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 10.6%
France Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.8%
France Market Earnings Growth Rate Market Cap Weighted Average 13.4%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:SAFOR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:SAFOR Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 21 1
2022-12-31 17 0 1
2021-12-31 11 -3 1
2020-12-31 8 -5 2
2019-12-31 5 -6 2
2018-12-31 3 -6 2
ENXTPA:SAFOR Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 3 -5 -6
2018-03-31 3 -5 -6
2017-12-31 3 -5 -7
2017-09-30 3 -6
2017-06-30 3 -5 -6
2017-03-31 3 -5 -6
2016-12-31 2 -6 -6
2016-09-30 2 -7
2016-06-30 2 -7 -7
2016-03-31 2 -7 -7
2015-12-31 2 -7 -7
2015-09-30 2 -6 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Safe Orthopaedics is high growth as no earnings estimate data is available.
  • Safe Orthopaedics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:SAFOR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Safe Orthopaedics Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:SAFOR Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31
ENXTPA:SAFOR Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.25
2018-03-31 -0.26
2017-12-31 -0.28
2017-09-30 -0.26
2017-06-30 -0.20
2017-03-31 -0.22
2016-12-31 -0.25
2016-09-30 -0.34
2016-06-30 -0.49
2016-03-31 -0.47
2015-12-31 -0.45
2015-09-30 -0.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Safe Orthopaedics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Safe Orthopaedics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Safe Orthopaedics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SAFOR Past Performance

  How has Safe Orthopaedics performed over the past 5 years?

  • Safe Orthopaedics's last earnings update was 205 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Safe Orthopaedics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Safe Orthopaedics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Safe Orthopaedics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Safe Orthopaedics's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Safe Orthopaedics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Safe Orthopaedics Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:SAFOR Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 3.13 -6.04 6.47
2018-03-31 3.12 -6.31 6.28
2017-12-31 3.11 -6.58 6.10
2017-09-30 2.91 -6.13 6.03
2017-06-30 2.71 -5.69 5.96
2017-03-31 2.54 -5.85 6.21
2016-12-31 2.37 -6.01 6.45
2016-09-30 2.43 -6.70 6.64
2016-06-30 2.49 -7.40 6.83
2016-03-31 2.50 -6.98 6.71
2015-12-31 2.50 -6.57 6.59
2015-09-30 2.43 -5.93 6.28
2015-06-30 2.35 -5.29 5.98
2015-03-31 2.20 -5.11 5.63
2014-12-31 2.05 -4.94 5.27
2014-09-30 1.78 -4.43 4.46
2014-06-30 1.51 -3.92 3.64
2014-03-31 1.24 -3.55 3.17
2013-12-31 0.97 -3.19 2.69
2012-12-31 0.33 -3.35 2.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Safe Orthopaedics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Safe Orthopaedics has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Safe Orthopaedics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Safe Orthopaedics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Safe Orthopaedics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SAFOR Health

 How is Safe Orthopaedics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Safe Orthopaedics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Safe Orthopaedics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Safe Orthopaedics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Safe Orthopaedics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Safe Orthopaedics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Safe Orthopaedics Company Filings, last reported 9 months ago.

ENXTPA:SAFOR Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -1.88 5.10 0.47
2018-03-31 -1.88 5.10 0.47
2017-12-31 1.06 5.18 3.74
2017-09-30 1.06 5.18 3.74
2017-06-30 -1.47 5.26 1.01
2017-03-31 -1.47 5.26 1.01
2016-12-31 0.37 6.01 3.66
2016-09-30 0.37 6.01 3.66
2016-06-30 2.72 4.73 4.32
2016-03-31 2.72 4.73 4.32
2015-12-31 5.09 3.43 5.92
2015-09-30 5.09 3.43 5.92
2015-06-30 8.11 1.06 6.10
2015-03-31 8.11 1.06 6.10
2014-12-31 2.46 1.05 0.99
2014-09-30 2.46 1.05 0.99
2014-06-30 5.16 0.85 4.22
2014-03-31 5.16 0.85 4.22
2013-12-31 -0.19 3.58 1.73
2012-12-31 1.17 1.35 2.00
  • Safe Orthopaedics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Safe Orthopaedics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Safe Orthopaedics has less than a year of cash runway based on current free cash flow.
  • Safe Orthopaedics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.6% each year.
X
Financial health checks
We assess Safe Orthopaedics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Safe Orthopaedics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SAFOR Dividends

 What is Safe Orthopaedics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Safe Orthopaedics dividends.
If you bought €2,000 of Safe Orthopaedics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Safe Orthopaedics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Safe Orthopaedics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:SAFOR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.6%
France Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 2.9%
France Minimum Threshold Dividend Yield 10th Percentile 0.9%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:SAFOR Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Safe Orthopaedics has not reported any payouts.
  • Unable to verify if Safe Orthopaedics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Safe Orthopaedics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Safe Orthopaedics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Safe Orthopaedics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Safe Orthopaedics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Safe Orthopaedics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SAFOR Management

 What is the CEO of Safe Orthopaedics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pierre Dumouchel
COMPENSATION €220,554
AGE 38
TENURE AS CEO 2.8 years
CEO Bio

Mr. Pierre Dumouchel Co-Founded Safe Orthopaedics SA in 2010 and has been its Chief Executive Officer since June 30, 2016. Mr. Dumouchel served as Head of Financial Control at Safe Orthopaedics SA since September 2017. He served as an Interim Chief Executive Officer of Safe Orthopaedics SA from March 2, 2016 to June 30, 2016. Mr. Dumouchel served as Industrialisation Director of Regulatory Affairs & Quality Director at Safe Orthopaedics SA and served as its Chief Operating Officer. He has developed a strong experience in the industrialization process mana-gement as well as quality system management for several spine projects before funding Safe Orthopaedics. He began his career in the automotive industry, before joining SpineVision in 2005 as Industrialization project leader for the PediGuard. In 2008, he took over responsibility for SpineVision’s industrialization department. In 2010, he co-founded Safe Orthopaedics and led the Industrialisation, Operations and Quality/Regulatory Affairs departments. He has 11 years’ experience in spinal medical devices industry. Mr. Dumouchel holds a Master’s Degree in both advanced Materials Engineering and in Management from the Conservatoire des Arts et Métiers and Institut Supérieur de Technologie et Management.

CEO Compensation
  • Pierre's compensation has been consistent with company performance over the past year.
  • Pierre's remuneration is higher than average for companies of similar size in France.
Management Team Tenure

Average tenure and age of the Safe Orthopaedics management team in years:

2.1
Average Tenure
42
Average Age
  • The tenure for the Safe Orthopaedics management team is about average.
Management Team

Pierre Dumouchel

TITLE
Co-Founder & CEO
COMPENSATION
€221K
AGE
38
TENURE
2.8 yrs

Dominique Petit

TITLE
Co-Founder
COMPENSATION
€309K
AGE
51
TENURE
9.3 yrs

Thomas Droulout

TITLE
Co-Founder & CTO
AGE
42
TENURE
9.3 yrs

François-Henri Reynaud

TITLE
Chief Financial Officer
TENURE
1.4 yrs

Sjors Hermans

TITLE
Global Sales Director
TENURE
0.8 yrs

Sven Claes

TITLE
Marketing Director
TENURE
0.8 yrs

Jochen Esser

TITLE
Head of Sales for Germany
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the Safe Orthopaedics board of directors in years:

2.3
Average Tenure
56.5
Average Age
  • The average tenure for the Safe Orthopaedics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Alain Coudray

TITLE
Chairman of the Board of Directors
COMPENSATION
€60K
TENURE
2.8 yrs

Dominique Petit

TITLE
Co-Founder
COMPENSATION
€309K
AGE
51
TENURE
2 yrs

Michael DeMane

TITLE
Director
COMPENSATION
€40K
AGE
61

Marie-Yvonne Landel

TITLE
Independent Director
COMPENSATION
€40K
AGE
65
TENURE
3.8 yrs

Jörg Franke

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Antonio Faundez

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Steven Van Gaalen

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Jean-Charles Le Huec

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Thierry Laugel

TITLE
Director
AGE
52
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Safe Orthopaedics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Safe Orthopaedics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SAFOR News

Simply Wall St News

How Safe Orthopaedics SA (EPA:SAFOR) Can Impact Your Portfolio Volatility

If you're interested in Safe Orthopaedics SA (EPA:SAFOR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Some Safe Orthopaedics Shareholders Have Taken A Painful 92% Share Price Drop

Safe Orthopaedics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. … In the last three years, Safe Orthopaedics saw its revenue grow by 10% per year, compound.

Simply Wall St -

What Kind Of Shareholder Appears On The Safe Orthopaedics SA's (EPA:SAFOR) Shareholder Register?

The big shareholder groups in Safe Orthopaedics SA (EPA:SAFOR) have power over the company. … Companies that used to be publicly owned tend to have lower insider ownership. … Safe Orthopaedics is not a large company by global standards.

Simply Wall St -

Is Safe Orthopaedics SA (EPA:SAFOR) A Volatile Stock?

If you're interested in Safe Orthopaedics SA (EPA:SAFOR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Who Owns Most Of Safe Orthopaedics SA (EPA:SAFOR)?

Today, I will be analyzing Safe Orthopaedics SA’s (EPA:SAFOR) recent ownership structure, an important but not-so-popular subject among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … Therefore, it is beneficial for us to examine SAFOR's ownership structure in more detail.

Simply Wall St -

Safe Orthopaedics SA's (EPA:SAFOR) Path To Profitability

Safe Orthopaedics, SA, a medical technology company, provides a range of sterile implants and associated single-use surgical instruments for use in spinal surgery in France. … The €9.94m market-cap company announced a latest loss of -€6.57m on 31 December 2017 for its most recent financial year result? … Check out our latest analysis for Safe Orthopaedics

Simply Wall St -

Safe Orthopaedics SA (EPA:SAFOR): What Does It Mean For Your Portfolio?

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … View our latest analysis for Safe Orthopaedics An interpretation of SAFOR's beta With a beta of 1.12, Safe Orthopaedics is a stock that tends to experience more gains than the market during a growth phase and also a bigger reduction in value compared to the market during a broad downturn. … SAFOR, with its market capitalisation of €11.66M, is a small-cap stock, which generally have higher beta than similar companies of larger size.

Simply Wall St -

Who Really Owns Safe Orthopaedics SA (EPA:SAFOR)?

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … Private Company Ownership Another important group of owners for potential investors in SAFOR are private companies that hold a stake of 10.82% in SAFOR. … Thus, investors should dig deeper into SAFOR's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: Institutional ownership level and composition in SAFOR is not high nor active enough to significantly impact its investment thesis.

Simply Wall St -

Safe Orthopaedics SA (EPA:SAFOR): Is It Growing Too Fast?

Check out our latest analysis for Safe Orthopaedics What is cash burn? … The measure of how fast Safe Orthopaedics goes through its cash reserves over time is called the cash burn rate. … My cash burn analysis suggests that, if Safe Orthopaedics continues to spend its cash reserves at this current high rate, it’ll have to raise capital within the next 2 months, which may be a surprise to some shareholders.

Simply Wall St -

Safe Orthopaedics SA (EPA:SAFOR): Is Breakeven Near?

I’ve put together a brief outline of industry analyst expectations for SAFOR, its year of breakeven and its implied growth rate. … Check out our latest analysis for Safe Orthopaedics Expectation from analysts is SAFOR is on the verge of breakeven. … ENXTPA:SAFOR Past Future Earnings Apr 4th 18 Given this is a high-level overview, I won’t go into detail the detail of SAFOR’s upcoming projects, though, bear in mind that by and large a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

Simply Wall St -

SAFOR Company Info

Description

Safe Orthopaedics, SA, a medical technology company, provides a range of sterile implants and associated single-use surgical instruments for use in spinal surgery in France. The company offers SteriSpine CC, a cervical cage system; SteriSpine PS, a pedicle screw system; and SteriSpine LC for the spinal segment. It also provides Oak, a percutaneous auto-correction screw system; Cypress, a modular anchorage screw system; and Cedar and Elm, which are leaner positioning cage systems. The company was founded in 2010 and is based in Eragny-sur-Oise, France.

Details
Name: Safe Orthopaedics SA
SAFOR
Exchange: ENXTPA
Founded: 2010
€6,344,441
41,197,673
Website: http://www.safeortho.com
Address: Safe Orthopaedics SA
Parc des Bellevues,
Allée R. Luxembourg,
Eragny-sur-Oise,
Ile-de-France, 95610,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA SAFOR Common Stock Euronext Paris FR EUR 10. Feb 2015
LSE 0RAA Common Stock London Stock Exchange GB EUR 10. Feb 2015
Number of employees
Current staff
Staff numbers
37
Safe Orthopaedics employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:46
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/19
Last earnings filing: 2018/09/28
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.